RNF43 p.G659fs 通过 PI3K/AKT/mTOR 信号通路和 HLA-E 上调导致 MSI-high 结直肠癌中 NK 细胞功能障碍
RNF43 p.G659fs leads to natural killer cell dysfunction in MSI-high colorectal cancer through PI3K/AKT/mTOR signaling and HLA-E up-regulation.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Dissecting immunosuppressive microenvironment in chemotherapy-resistant colorectal cancer through single-cell transcriptomic analysis.
Dissecting immunosuppressive microenvironment in chemotherapy-resistant colorectal cancer through single-cell transcriptomic analysis.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
这张全面的单细胞图谱揭示了化疗耐药 CRC 的多维免疫抑制景观,识别了驱动免疫逃逸的协同细胞、分子和空间机制。我们的发现为预测治疗耐药提供了候选生物标志物,并突出了治疗脆弱性,可用于开发基于免疫治疗的联合策略以克服 CRC 中的化疗耐药。
结直肠癌(CRC)仍是癌症相关死亡的主要原因,化疗耐药是有效治疗的关键障碍。肿瘤微环境(TME)通过复杂的免疫抑制机制在介导耐药中发挥关键作用,而这些机制在细胞分辨率层面仍未完全阐明。
我们对来自化疗敏感和耐药CRC标本的13,380个细胞进行了全面的单细胞RNA测序分析。经过严格的质量控制和降维后,我们进行了无监督聚类、细胞类型注释、差异表达分析、功能富集评估、轨迹推断以及细胞-细胞相互作用网络重建。使用化疗耐药细胞系(HCT116-OxR和SW480-5FUR)通过定量RT-PCR和ELISA实验进行了体外验证。
单细胞分析揭示,耐药肿瘤中TME发生了深刻重塑,其特征为:(1) 组成发生显著改变,细胞毒性T细胞和NK细胞群体减少,调节性T细胞和M2极化巨噬细胞增加;(2) T细胞活化通路被系统性抑制(标准化富集分数 = -2.8,FDR < 0.001),同时免疫抑制程序上调,包括缺氧反应、血管生成和代谢适应;(3) 抑制性细胞间通讯网络增强,表现为PD-L1/PD-1、CTLA-4、TGF- 和IL-10信号升高;(4) T细胞轨迹从细胞毒性效应表型向耗竭表型逐步转变;(5) 免疫检查点分子(PD-L1、TIM-3、LAG-3)、抑制性细胞因子(TGF- 1、IL-10)和代谢酶(IDO1、ARG1)协同上调。体外验证证实,耐药细胞系表现出2.3-5.1倍的转录上调,并显著增强免疫抑制因子(PD-L1、TGF- 1、IDO1、IL-10;均p < 0.001)的分泌。
Colorectal cancer (CRC) remains a leading cause of cancer-related mortality, with chemotherapy resistance representing a critical barrier to effective treatment. The tumor microenvironment (TME) plays a pivotal role in mediating resistance through complex immunosuppressive mechanisms that remain incompletely understood at cellular resolution.
We performed comprehensive single-cell RNA sequencing analysis on 13,380 cells from chemotherapy-sensitive and resistant CRC specimens. Following rigorous quality control and dimensional reduction, we conducted unsupervised clustering, cell type annotation, differential expression analysis, functional enrichment assessment, trajectory inference, and cell-cell interaction network reconstruction. In vitro validation was performed using chemotherapy-resistant cell lines (HCT116-OxR and SW480-5FUR) with quantitative RT-PCR and ELISA assays.
Single-cell analysis revealed profound TME remodeling in resistant tumors characterized by: (1) significant compositional shifts with reduced cytotoxic T cell and NK cell populations and increased regulatory T cells and M2-polarized macrophages; (2) systematic suppression of T cell activation pathways (normalized enrichment score = -2.8, FDR < 0.001) with concurrent upregulation of immunosuppressive programs including hypoxia response, angiogenesis, and metabolic adaptation; (3) enhanced inhibitory cell-cell communication networks featuring elevated PD-L1/PD-1, CTLA-4, TGF- , and IL-10 signaling; (4) progressive T cell trajectory transitions from cytotoxic effector to exhausted phenotypes; (5) coordinated upregulation of immune checkpoint molecules (PD-L1, TIM-3, LAG-3), inhibitory cytokines (TGF- 1, IL-10), and metabolic enzymes (IDO1, ARG1). In vitro validation confirmed that resistant cell lines exhibited 2.3-5.1-fold transcriptional upregulation and significantly enhanced secretion of immunosuppressive factors (PD-L1, TGF- 1, IDO1, IL-10; all p < 0.001).
This comprehensive single-cell atlas reveals the multi-dimensional immunosuppressive landscape of chemotherapy-resistant CRC, identifying coordinated cellular, molecular, and spatial mechanisms driving immune evasion. Our findings provide candidate biomarkers for predicting treatment resistance and highlight therapeutic vulnerabilities for developing immunotherapy-based combination strategies to overcome chemotherapy resistance in CRC.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。